Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Mar 09, 2012 11:47am

352 Views

Post# 19649519

RE: RE: RE: RE: RE: RE: RE: RE: Paradigm

" Management should be ashamed of itself. They know they need to communicate more, explain missed milestones/dates, but they don't."

Why should they? They're too busy counting their cheap options, submitting their travel expense claims and cashing their generous salary cheques to bother with we lowly shareholders. Remember the issuing of $3+ options were precipitated by a 50% drop in the SP, an issue I'm still waiting for a answer to, re: my e-mail.

Bullboard Posts

Arbor Metals completes Phase 1 drilling at Jarnet lithium project